M2 Receptor Activation Counteracts the Glioblastoma Cancer Stem Cell Response to Hypoxia Condition
Glioblastoma multiforme (GBM) is the most malignant brain tumor. Hypoxic condition
is a predominant feature of the GBM contributing to tumor growth and resistance to conventional
therapies. Hence, the identification of drugs able to impair GBM malignancy and aggressiveness
is considered of great clinical relevance. Previously, we demonstrated that the activation of M2
muscarinic receptors, through the agonist arecaidine propargyl ester (Ape), arrests cell proliferation